ContraFect

+$0.11 (+2.56%) As of 1:12 PM UTC pre-market

Why Robinhood?

You can buy or sell ContraFect and other stocks, options, and ETFs commission-free!

About CFRX

ContraFect Corporation Common Stock, also called ContraFect, is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides.

CEO
Roger J. Pomerantz
Employees
33
Headquarters
Yonkers, New York
Founded
2008

CFRX Key Statistics

Market Cap
168.74M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
210.15K
High Today
$4.35
Low Today
$4.24
Open Price
$4.25
Volume
164.35K
52 Week High
$8.00
52 Week Low
$3.44

CFRX Earnings

-$0.88
-$0.59
-$0.29
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 13, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure